Frontlight ResearchEarly access
Active, not recruitingPhase 1
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
Key facts
- Who runs it
- Case Comprehensive Cancer Center
- Where
- Cleveland, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 33 people enrolled
- Started
- 2 Jul 2013
- Ended
- Aug 2025
- Type of study
- Interventional
- Treatments tested
- stereotactic radiosurgery
- quality-of-life assessment
- cognitive assessment
- Record updated
- 20 July 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Any patient undergoing SRS for brain metastases
- Lesions to be treated under this protocol must be > 2 cm, but =< 4.0 cm in diameter
- Patients may have had prior therapy including:; Whole brain radiation therapy (WBRT) > 3 months ago; SRS to other brain metastases
- Patients with newly diagnosed brain metastases are eligible as long as they are not planned for WBRT upfront
- Any primary is eligible with exception of small cell lung cancer, lymphoma, and germ cell histologies
- Patient must be able to provide written informed consent
Who cannot take part
- Patients receiving SRS to resection bed
- Planned concurrent WBRT
- Small cell lung cancer, lymphoma, and germ cell histologies
- Leptomeningeal metastases
- Inability to participate in study activities due to physical or mental limitations
- Inability or unwillingness to return for all the required follow-up visits
- Conformality index 2.0 or less cannot be achieved, or homogeneity index is > 2.0
- Unable to deliver 10 Gray (Gy) or less to optic nerve/chiasm
- Brainstem location is excluded from this study
Where in United States
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer CenterCleveland, United States
About the trial
What the trial wants to find out
This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.
The group in the trial
- Treatment (SRS)Treatment being tested
Patients undergo SRS guided by CT and MRI.
Treatment: stereotactic radiosurgery, quality-of-life assessment, and cognitive assessment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dose Escalation for Larger Brain Metastases: Phase I/II Study
- Record updated
- 20 July 2025